KSI-101 is a first-in-class, high-strength intravitreal biologic designed to target IL-6 mediated inflammation and VEGF-mediated vascular permeability simultaneously VEGF IL-6 IL-6 KSI-101: high formulation strength (100 mg/mL) 57